EQS-Adhoc: BB Biotech AG publishes its interim report

Ad hoc announcement pursuant to Art. 53 LR

October 20, 2023

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2023, which covers the results of its business activities for the first nine months of 2023.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended September 30, 2023 amounted to CHF 316 mn (loss of CHF 323 mn in the same period 2022). In the third quarter a loss of CHF 48 mn (profit of CHF 210 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG’s interim report as at September 30, 2023 is available under report.bbbiotech.ch/Q323 or www.bbbiotech.com.

For further information:

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile 
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.

1752885  20-Oct-2023 CET/CEST